Liver Disease Clinical Trial
Official title:
Development and Feasibility Testing of a Behavioural Intervention Targeting Multiple Lifestyle Behaviours to Improve Long Term Outcomes Following Liver Transplantation
(i) To develop a behavioural intervention that supports healthcare professionals to
effectively deliver lifestyle behaviour change of patients undergoing liver transplantation
(ii) To assess the acceptability and feasibility of the behavioural intervention during
routine practice
BACKGROUND
Liver transplantation is the most effective treatment for decompensated chronic liver
disease and is associated with improvements in life expectancy and quality of life(1).
Recent advances in immunosuppressive therapy; greater surgical and anaesthetic expertise and
optimised risk assessment procedures have shown to be associated with improvements in 90
day, 1 and 5 year survival (2). However, non-liver causes of death are on the increase with
malignancy (22%), cardiovascular disease (11%), infection (9%) and renal failure (6%)
becoming leading causes of death at one year (3)
It is well recognised that liver transplantation is associated with the onset of a number of
conditions that increase risk of early mortality, including new onset diabetes, hypertension
and dyslipidaemia (4,5). These conditions have the potential to be prevented or improved by
behavioural intervention targeting health and lifestyle behaviours including physical
activity, diet, smoking and medication adherence (6). Lifestyle factors are central to both
survival on the waiting list and long-term post transplant survival. Therefore it is
important to support patients to make positive and sustainable lifestyle behaviour changes.
However, this represents a complex medical challenge because rarely are clinical teams
trained to target lifestyle behaviour change in a meaningful/personalised way.
AIMS OF THE STUDY
The aim is to develop a behavioural intervention that can be used by all medical personnel
involved in the care of patients being assessed for transplantation, whilst listed for
transplantation and post transplantation to improve long-term outcomes. The intervention
will be co-developed by clinicians and patients to ensure it is fit for purpose. Healthcare
professionals will be trained to target a range of health and lifestyle behaviours using
evidence-based behavioural strategies. It is hoped this will lead to improvements in
long-term survival by reducing modifiable risk factors for mortality.
OBJECTIVES
This study will develop and assess acceptability and feasibility of a multifaceted behaviour
change intervention. The intervention will be designed to train healthcare professionals to
use behavioural strategies to target key lifestyle behaviours in the context of liver
transplantation, and to equip patients with behavioural skills to make positive changes to a
range of lifestyle behaviours. In reality, this could be the most cost effective model to be
able to enable lifestyle change for transplant patients. These healthcare professionals are
front line staff and work with high volumes of transplant patients.
PRIMARY RESEARCH QUESTION Is a multifaceted behavioural intervention co-developed by
healthcare professionals and patients acceptable and feasible and can it be delivered
faithfully during routine clinical practice?
Objectives The objectives of this study are:- i) To co-develop an evidence-based,
multifaceted behavioural intervention for delivery during routine clinical consultations ii)
To develop a training programme that equips clinicians with the knowledge, skills and
confidence to deliver a behavioural intervention during routine clinical practice iii) To
determine whether the behavioural intervention is acceptable and feasible to both healthcare
professionals and patients iv) To assess whether the behavioural intervention can be
delivered faithfully during routine clinical practice v) To optimise the behavioural
intervention based on feedback from clinicians and patients.
vi) To assess whether the intervention impacts positively on clinical outcomes (e.g., blood
pressure, HbA1c levels) vii) To inform the design of a large randomised controlled trial if
appropriate
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02798861 -
Controlled Attenuation Parameter (CAP) in Liver Allografts
|
||
Completed |
NCT01968395 -
Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure
|
Phase 4 | |
Completed |
NCT01437969 -
Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
|
||
Recruiting |
NCT00155376 -
Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography
|
Phase 4 | |
Recruiting |
NCT00172705 -
Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique
|
N/A | |
Completed |
NCT04185454 -
Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese
|
N/A | |
Completed |
NCT02506335 -
Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease
|
Early Phase 1 | |
Completed |
NCT02520609 -
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
|
||
Completed |
NCT02306018 -
Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation
|
N/A | |
Completed |
NCT01970904 -
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
|
N/A | |
Completed |
NCT01988753 -
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
|
||
Terminated |
NCT00741117 -
Conjugated Hyperbilirubinemia and Pulse Oximetry
|
N/A | |
Enrolling by invitation |
NCT01483248 -
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
|
Phase 1/Phase 2 | |
Completed |
NCT00245830 -
Ischemic Preconditioning of Liver in Cadaver Donors
|
N/A | |
Completed |
NCT00074386 -
Kidney and Liver Transplantation in People With HIV
|
N/A | |
Completed |
NCT02329821 -
Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection
|
N/A | |
Completed |
NCT01650181 -
Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis
|
Phase 4 | |
Completed |
NCT01303549 -
Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
|
Phase 4 | |
Completed |
NCT00799851 -
A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices
|
Phase 4 | |
Completed |
NCT00058890 -
Gabapentin to Treat Itch in Patients With Liver Disease
|
Phase 3 |